Journal article
Utility of an improved model of amyloid-beta (Aβ1-42) toxicity in Caenorhabditis elegans for drug screening for Alzheimer's disease
G Mccoll, BR Roberts, TL Pukala, VB Kenche, CM Roberts, CD Link, TM Ryan, CL Masters, KJ Barnham, AI Bush, RA Cherny
Molecular Neurodegeneration | Published : 2012
Abstract
Background: The definitive indicator of Alzheimer's disease (AD) pathology is the profuse accumulation of amyloid-ß (Aß) within the brain. Various in vitro and cell-based models have been proposed for high throughput drug screening for potential therapeutic benefit in diseases of protein misfolding. Caenorhabditis elegans offers a convenient in vivo system for examination of Aß accumulation and toxicity in a complex multicellular organism. Ease of culturing and a short life cycle make this animal model well suited to rapid screening of candidate compounds. Results: We have generated a new transgenic strain of C. elegans that expresses full length Aß1-42. This strain differs from existing Aß ..
View full abstractGrants
Awarded by National Institute on Aging
Funding Acknowledgements
We thank Leanne Taylor and Ian Birchall (FNIMH) for assistance with histology, Monica Lind (FNIMH) for technical assistance and Nicole Jenkins for comments. Nematode strains used include some provided by the Caenorhabditis Genetics Center funded by the U. S. National Institutes of Health National Center for Research Resources. We acknowledge support by the Victorian Government Operational Infrastructure Support Program.